Article source：
Sep 02,2026
View：
122 On July 24, The 1st China Pharmaceutical innovation Conference 2026 was successfully held. The “Biosimilars Commercialization & Global Launch Session(China Focus) ,” jointly organized by Kexing Biopharm (688136.SH), Tongxieyi and Thousand Oaks, served as a key agenda focused on the internationalization of biosimilars at CPIC 2026. The session brought together experts from across the industry value chain, including industry research, global pharmaceutical data intelligence, CDMO and commercialization, presenting attendees with a comprehensive industry dialogue on how Chinese biosimilars can expand into global markets.
Zhu Xun, Founding Chairman of Tongxieyi New Drug Talent Club
Zhu Xun, Founding Chairman of the Tongxieyi New Drug Talent Club, opened the session with a presentation titled “Analysis of the Development Path of Chinese Biosimilars.” Looking back at the development of China’s biologics industry, he reviewed its evolution from early-stage generic imitation and follow-up to innovation-driven breakthroughs in recent years, systematically outlining the development of biosimilars from R&D to commercialization.
Zhu Xun pointed out that China’s biopharmaceutical industry has no shortage of high-quality products. What is truly scarce, however, is the kind of company capable of bringing these high-quality products to global markets. His observation resonated strongly with industry participants and established a pragmatic tone for the entire session.
Bai Han, Principal, Custom Solutions, APAC, Norstella
From the perspective of global market assessment, Bai Han, Principal, Custom Solutions, APAC at Norstella, delivered an analysis titled “Opportunities and Strategic Choices for Chinese Enterprises Under the New Global Landscape of Biosimilars.”
He examined the opportunities available to Chinese companies seeking to expand overseas from multiple dimensions, including market access mechanisms, clinical strategies and business models. He noted that by 2031, biologic drugs with a cumulative value of nearly US$250 billion will face patent expiration globally.
The winners in the biosimilar market, he emphasized, will not simply be “cheaper copies,” but organizations capable of integrating themselves into the value chain encompassing procurement, market access, prescribing and product switching.
Ma Jun, Vice President of R&D, TOBIO Group
Moving from strategic assessment to industrial implementation, Ma Jun, Vice President of R&D at TOBIO (Thousand Oaks Biologics) Group, provided a systematic overview of the critical stages involved in biosimilar development and production, from cell line development and process scale-up to GMP-compliant manufacturing.
As one of the relatively few domestic upstream CRDMO companies with commercial biologics production experience, Thousand Oaks’s large-scale delivery capabilities in biosimilar CMC provide an essential industrial foundation for Chinese biosimilars seeking to enter international markets.
Max Fernandez, Chief Global Growth & Operations Officer (CGOO),Intellective Biologics (Suzhou) Co., Ltd.
Max Fernandez, Chief Global Growth & Operations Officer (CGOO) of ,Intellective Biologics (Suzhou) Co., Ltd., brought an international perspective to the discussion.
He emphasized that China’s biosimilar industry is now at a critical turning point, transitioning from a “follower” to a “pioneer.” The key to this transformation lies in leveraging existing resources and integrating the broader industry ecosystem through systematic collaboration, thereby enabling Chinese biosimilars to reach global markets more effectively and improving patient access to high-quality biologic medicines.
Shao Ke, Deputy General Manager, Kexing Biopharm
How can industry resources be integrated to accelerate global expansion? Session moderator Shao Ke, Deputy General Manager of Kexing Biopharm (688136.SH), introduced Kexing Biopharm’s strategic positioning as a platform for Chinese biologics to expand overseas. He also explained the logic behind the rapid growth of the company’s international business, highlighting its ability to efficiently initiate registrations across multiple countries and its extensive global commercialization network.
In recent years, Kexing Biopharm’s overseas commercialization platform has provided professional global expansion services for multiple high-quality medicines developed by Chinese pharmaceutical companies.
The session featured two roundtable discussions, which brought the atmosphere to a climax. The first focused on “Joint Efforts for Mass Production: Large-Scale Manufacturing and Cost Optimization of Biosimilars,” while the second explored “Global Biosimilar Industry: Opportunities, Challenges and the Global Rise of China’s Biopharma.”
The first roundtable was moderated by Luo Jiali, CEO of TOBIO (Thousand Oaks Biologics) Group, with Huang Xueying, Chairman of Sepa Chrom Technology; Zhou Sheng, Deputy General Manager of Lishui Technology; Xie Hongyan, Vice President of Cobetter; and Ma Jun, Vice President of R&D at TOBIO (Thousand Oaks Biologics) Group participating in the discussion.
The panel examined key challenges facing large-scale biosimilar production, including process stability, cost control, domestic substitution and supply chain security. The discussion demonstrated how an independent and controllable industrial foundation can be established from the manufacturing side.
The second roundtable was moderated by Shao Ke, Deputy General Manager of Kexing Biopharm, with Mi Zihou, President of IQVIA Asia Pacific; Luo Jiali, CEO of TOBIO (Thousand Oaks Biologics) Group; Dou Changlin, CEO and Chief Scientific Officer of Anhui AnKe Biotechnology; and Sun Handong, Deputy General Manager & Director of R&D Center at Jiuyuan Gene joining the discussion.
From CXO enablement, commercialization platforms and global clinical development to industrial innovation, the panel explored multiple dimensions of international development and outlined potential pathways for Chinese biosimilars to enter and compete in global markets.
As Chinese innovation gains an increasingly influential voice on the global stage, biologics are gradually entering an accelerated phase in which accumulated capabilities are being transformed into commercial value.
The 1st China Pharmaceutical innovation Conference 2026 Global Conference — Biosimilars Commercialization & Global Launch Session(China Focus) provided an in-depth dialogue ranging from macro-level industry assessment to practical implementation, and from China’s industrialization capabilities to global market trends. The discussions offered a vivid illustration of how China’s biopharmaceutical industry is progressing from “Big-Country Innovative Drugs” to “High-Quality Medicines for the World.”
BACK TO LIST
Jul 13,2023
